No Data
No Data
BioXcel Therapeutics Announces DOD Grant to UNC to Fund Study of BXCL501
Express News | BioXcel Therapeutics Inc - Phase 2a Trial Enrollment Expected in H1 2025
Express News | BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
No Data
No Data